Key takeaways
- We found six studies that gave BPC-157 to people, 118 participants in total, and four ClinicalTrials.gov entries (18 Nov 2026).
- The only randomised, placebo-controlled data come from conference abstracts on two studies (2002 to 2005); FDA staff found the colitis trial’s data inadequate.
- A 2026 systematic review of the three full papers rated the certainty of the evidence “very low”.
- None of the four registered studies has posted results; a phase 2 trial is recruiting.
- According to FDA staff, no serious adverse events appear to have been reported in the five studies they reviewed, but safety monitoring was unclear and the safety profile cannot be characterised.
01BPC-157 human studies at a glance
Every study we found that gave BPC-157 to people, counted on 18 November 2026 from PubMed, ClinicalTrials.gov and FDA’s 2026 review.
| Question | Answer (18 Nov 2026) |
|---|---|
| Studies that gave BPC-157 to people | 6, two of them known only from conference abstracts summarised in FDA’s 2026 review |
| People in them, in total | 118, including placebo groups (32 + 53 + 16 + 12 + 2 + 3) |
| Randomised and placebo-controlled | 2, both known only from conference abstracts (2002–2005); no full peer-reviewed paper |
| Registry entries on ClinicalTrials.gov | 4: 1 completed, 1 recruiting, 1 not yet recruiting, 1 of unknown status |
| Registry entries with posted results | 0 |
| Evidence tier | T2: small human studies, most without a control group. The main evidence base is animal (T3) |
| Certainty, per a 2026 systematic review | “Very low” |
02Published human studies
FDA staff found five clinical studies when they reviewed BPC-157 for the July 2026 advisory committee. A 2026 case report adds a sixth. A 2026 systematic review, searching to 1 June 2026, included three full papers.
| Study | Design | People (n) | What was measured | Control group |
|---|---|---|---|---|
| Veljaca et al., 2002 and 2003 (conference abstracts) | Phase 1, randomised, placebo-controlled | 32 healthy volunteers, 24 given BPC-157 | Tolerability and blood levels | Placebo |
| Ruenzi et al., 2005 (conference abstract) | Phase 2, randomised, double-blind, placebo-controlled, multicentre | 53 with mild to moderate ulcerative colitis; 46 completed | A disease-activity score | Placebo |
| Lee and Padgett, 2021 | Retrospective chart review with a phone survey | 16 with knee pain, 4 of whom also received thymosin β4 | Self-rated pain relief | None |
| Lee, Walker and Ayadi, 2024 | Single-arm pilot | 12 women with interstitial cystitis | A global response questionnaire | None |
| Lee and Burgess, 2025 | Pilot safety study | 2 adults | Blood tests and vital signs | None |
| Froum et al., 2026 | Case report | 3 dental patients with nerve injury, given several agents at once | Recovery of sensation | None |
What FDA staff said. The studies “were of short duration, had small sample sizes”, and the authors “provided limited information on safety data”. On the colitis trial, known only from a meeting abstract, they concluded that the data “are therefore inadequate to support the efficacy and safety” of BPC-157 in that setting. In the two abstract-only studies, BPC-157 was reported as not detected, or mostly below the assay’s limit, in blood samples.
What the 2026 systematic review said. Reviewing the three full papers (30 people), the authors judged all three to be of poor methodological quality and rated the overall certainty of the evidence “very low”. None had a control group, so none can separate an effect of BPC-157 from natural recovery or expectation.
03Registered human studies
ClinicalTrials.gov lists four studies of BPC-157 in people. None has posted results.
| Record | Design | People | Primary outcome | Status | Results posted |
|---|---|---|---|---|---|
| NCT02637284 | Phase 1, randomised, placebo-controlled, blinded | 42 healthy volunteers (estimated) | Adverse events | Unknown; last updated December 2015 | No |
| NCT07752381 | Single group, no control, not blinded | 40 physically active adults (actual) | Blood markers of inflammation (hs-CRP, IL-6) and self-reported swelling | Completed November 2025 | No |
| NCT07437547 | Phase 2, randomised, placebo-controlled, quadruple-blind | 120 adults with an MRI-confirmed hamstring strain (estimated) | Time to return to sport; change in injury volume on MRI | Recruiting since February 2026 | No |
| NCT07803250 | Phase 1, randomised, blinded | 30 adults after rotator cuff repair surgery (estimated) | Shoulder strength | Not yet recruiting; planned start January 2027 | No |
NCT07752381 tested a commercial product containing BPC-157, made by the study’s sponsor. For NCT02637284, FDA staff found no posted results and no associated published study. NCT07803250’s record is internally inconsistent: its summary describes 20 patients and a saline placebo, while its arms list a control group with no study product and an estimated enrolment of 30. A registration is a plan, not a result.
04Safety in these studies
FDA staff found that no serious adverse events appear to have been reported in the five studies they reviewed. They caution that safety monitoring for most of them “is unclear”, and concluded that “there is insufficient clinical safety information to characterize the safety profile” of BPC-157. In the healthy-volunteer abstracts, headache and flatulence were the most frequent adverse events, with no obvious difference from placebo.
Outside these studies, FDA found three FAERS reports through 4 December 2025, all involving injectable products: redness and swelling at the injection site in a person also using thymosin; shortness of breath leading to an emergency-room visit; and skin and gum darkening that came back when the person used a product containing BPC-157 and TB-500 again. FDA staff judged that last case “likely due to the drug product”, but, because the product contained two peptides, could not assess whether BPC-157 played a role, and wrote that FDA “cannot make definitive conclusions regarding the safety of BPC-157 based on FAERS data alone”.
FDA’s compounding page adds that BPC-157 “may pose risk for immunogenicity for certain routes of administration” and that the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans”. If you have had a reaction to any peptide product: how to report it.
05What these studies can’t tell you
- Whether BPC-157 works for any condition in people. The only randomised data sit in two conference abstracts: one was a tolerability study, and FDA staff found the other, in colitis, inadequate to support efficacy or safety.
- Its safety over months or years. FDA staff describe the studies as short and small, with unclear safety monitoring.
- How BPC-157 behaves in the human body. FDA staff found no human pharmacokinetic data for most routes, and in the two studies that measured blood levels BPC-157 was not detected or mostly below the assay’s limit.
- What the registered trials will find. None has reported.
For the animal research and regulatory history, see the BPC-157 research guide and is BPC-157 legal?
Counts and statuses checked on 18 Nov 2026. This page summarises research. It is not medical advice.